Document is current

Article History

Received: 4 April 2024

Accepted: 14 June 2024

First Online: 28 July 2024

Declarations

:

: MMa has no conflict of interest within the present work. Outside of it, MMa is or recently was a speaker and/or advisor for and/or has received research funding from Allakos, Alvotech, Amgen, Aquestive, Aralez, AstraZeneca, Astria, Bayer, BioCryst, Blueprint, Celldex, Celltrion, Centogene, CSL Behring, Evoemmune, GSK, Ipsen, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Mitsubishi Tanabe Pharma, Moxie, Noucor, Novartis, Orion Biotechnoloy, Pharvaris, Resonance Medicine, Sanofi/Regeneron, Septerna, Takeda, Teva, Trial Form Support International AB, Third HarmonicBio, Valenza Bio, Yuhan Corporation, and Zurabio. MMe has no conflict of interest within the present work. Outside of it, MMe is or recently was a speaker and/or advisor for AbbVie, Amgen, AstraZeneca, argenx, Bayer, Beiersdorf, Celldex, Escient, Galderma, gsk, Incyte, Jasper, Novartis, Pharvaris, Pfizer, Sanofi-Aventis, Teva, ThirdHarmonicBio, Vifor. MHu, JS, SF, CS, UR, MS, KP, MHa, TH have no conflict of interest to declare.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Charité – Universitätsmedizin Berlin (EA1/007/14, EA1/235/13).

: Informed consent was obtained from all individual participants included in the study.

: All listed authors have seen and approved of the manuscript and will sign off on any subsequent manuscript revisions. The article does not contain any identifying information about the participants.